☰ 目次
2023 HRS/APHRS/LAHRS Guideline on Cardiac Physiologic Pacing for the Avoidance and Mitigation of Heart Failure
Heart Rhythm Society・2023・75 ページ · 不整脈・デバイス・アブレーション · 心不全・心筋症 · 腎臓・透析
目次 閉じる
Gopi Dandamudi, MBA, MD, FHRS,13,* Anne M. Dubin, MD, FHRS, CEPS-P,14,‡1 Win-Kuang Shen, MD, FHRS,41,* Morio Shoda, MD, PhD,42,#1 Top 10 take-home messages4 Other important considerations4 1.2 Document scope, objectives, and assumptions5 1.3 Editorial independence6 1.4 Organization of the writing committee and6 1.5 Evidence review and formulation of6 1.6 Class of recommendation and level of evidence7 1.7 Document review and approval8 1.8 Document updates8 1.9 Other guideline documents and systematic8 2.1 Definitions8 2.2 Epidemiology, pathophysiology, and detection10 1 B-NR10 3.1 Patients with indications for pacemaker11 3.2 Indications for CPP in patients with HF16 104 2b B-R17 108 C-LD (HBP, LBBAP)22 1 B-NR23 29 2a B-NR23 3.3 Combination CRT with LV (CS LV or LV24 1 C-EO24 3.4 Indications for CPP in AF25 4.1 Preprocedure testing29 1 A (CRT)29 4.2 Assessment for other predictive factors30 4.3 Shared decision-making30 1 C-EO30 5.1 Tools and techniques for CRT with BiV pacing32 1 B-R32 5.2 Tools and techniques for CSP34 1 C-EO35 5.3 When to consider alternative CPP sites39 Time41 6.1 Follow-up evaluations42 1 B-NR (CRT)42 6.2 Role of a dedicated CRT clinic43 6.3 Optimization of CPP response44 1 B-NR44 6.4 Replacement or upgrade considerations45 1 C-EO45 1 B-NR45 6.5 Troubleshooting for unfavorable response46 1 C-LD46 6.6 When to cross over to CSP, CRT, or epicardial47 7.1 CHD49 409 2b C-LD49 7.2 Pediatric patients without CHD51 References54
p.1
p.2
p.3
p.4
p.5
p.6
p.7
p.8
p.9
p.10
p.11
p.12
p.13
p.14
p.15
p.16
p.17
p.18
p.19
p.20
p.21
p.22
p.23
p.24
p.25
p.26
p.27
p.28
p.29
p.30
p.31
p.32
p.33
p.34
p.35
p.36
p.37
p.38
p.39
p.40
p.41
p.42
p.43
p.44
p.45
p.46
p.47
p.48
p.49
p.50
p.51
p.52
p.53
p.54
p.55
p.56
p.57
p.58
p.59
p.60
p.61
p.62
p.63
p.64
p.65
p.66
p.67
p.68
p.69
p.70
p.71
p.72
p.73
p.74
p.75
🔍 検索
💬 AI
📚 閲覧
☰ 一覧
🔔 更新3